Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28, 2022, at 12:00 pm ET
March 23 2022 - 8:30AM
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with cancer, announced today that
management will participate in a panel discussion titled,
“Pancreatic Cancer- Turning the Tide for One of the Most
Challenging Indications in Oncology,” at the Maxim Virtual Growth
Conference on March 28, 2022, at 12:00 pm ET.
In addition to participating in the panel, the company will also
give a presentation during the event available to viewers on-demand
for the duration of the conference – March 28-30, 2022.
The growth conference is powered by Maxim Group’s MVEST platform
and will stream virtually at:
https://m-vest.com/events/2022-virtual-growth-conference.
About: SBP-101SBP-101 is a proprietary
polyamine analogue designed to induce polyamine metabolic
inhibition (PMI) by exploiting an observed high affinity of the
compound for pancreatic ductal adenocarcinoma and other tumors. The
molecule has shown signals of tumor growth inhibition in clinical
studies of US and Australian metastatic pancreatic cancer patients,
demonstrating a median overall survival (OS) of 12.53 months which
is now final, and an objective response rate (ORR) of 48%, both
exceeding what is seen typically with the standard of care of
gemcitabine + nab-paclitaxel suggesting potential complementary
activity with the existing FDA-approved standard chemotherapy
regimen. In data evaluated from clinical studies to date, SBP-101
has not shown exacerbation of bone marrow suppression and
peripheral neuropathy, which can be chemotherapy-related adverse
events. Serious visual adverse events have been evaluated and
patients with a history of retinopathy or at risk of retinal
detachment will be excluded from future SBP-101 studies. The safety
data and PMI profile observed in the current Panbela sponsored
clinical trial provides support for continued evaluation of SBP-101
in a randomized clinical trial. For more information, please
visit https://clinicaltrials.gov/ct2/show/NCT03412799 .
About PanbelaPanbela Therapeutics, Inc. is a
clinical-stage biopharmaceutical company developing disruptive
therapeutics for patients with urgent unmet medical needs. The
company’s initial product candidate, SBP-101, is for the treatment
of patients with metastatic pancreatic ductal adenocarcinoma, the
most common type of pancreatic cancer. Panbela Therapeutics, Inc.
is dedicated to treating patients with pancreatic cancer, ovarian,
and exploring SBP-101’s potential for efficacy in combination with
other agents in other cancer indications. Further information can
be found at www.panbela.com. Panbela
Therapeutics, Inc. common stock is listed on The Nasdaq Stock
Market LLC under the symbol PBLA.
Cautionary Statement Regarding Forward-Looking
StatementsThis press release contains
“forward-looking statements,” including within the meaning of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “believe,” “could,”
“expect,” “feel,” “intend,” “may,” “plan,”
“positioned, “and “scheduled,” and “will”. Examples of
forward-looking statements include statements we make regarding our
potential expanded pipeline and upcoming milestones. All statements
other than statements of historical fact are statements that should
be deemed forward-looking statements. Forward-looking
statements are neither historical facts nor assurances of future
performance. Instead, they are based only on our current
beliefs, expectations, and assumptions regarding the future of our
business, future plans and strategies, projections,
anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties, risks and
changes in circumstances that are difficult to predict and many of
which are outside of our control. Our actual results and
financial condition may differ materially and adversely from the
forward-looking statements. Therefore, you should not rely on
any of these forward-looking statements. Important factors
that could cause our actual results and financial condition to
differ materially from those indicated in the forward-looking
statements include, among others, the following: (i) risks
related to the consummation of the mergers, including the risks
that (a) the mergers may not be consummated within the anticipated
time period, or at all, (b) failure of our stockholders to approve
the issuance of shares contemplated by the merger agreement, (c)
other conditions to the consummation of the mergers under the
merger agreement may not be satisfied, and (d) the significant
limitations on remedies contained in the merger agreement may limit
or entirely prevent Panbela from specifically enforcing CPP’s
obligations under the merger agreement or recovering damages for
any breach; (ii) approval of the combined company’s application to
list its shares on Nasdaq; (iii) no assurance that future
developments affecting CPP will occur as anticipated; (iv) the
effects that any termination of the merger agreement may have on
Panbela or its business, including risk that the price of Panbela
common stock may decline significantly if the mergers are not
completed; (v) the effects that the announcement or pendency of the
mergers may have on Panbela and its operations, including the risks
that as a result (a) operating results or stock price of Panbela
may suffer, (b) its current plans and operations may be disrupted,
(c) the ability of Panbela to retain or recruit key employees may
be adversely affected, (d) its business relationships
(including, clinicians, CROs and suppliers) may be adversely
affected, or (e) management and employee attention may be diverted
from other important matters; (vi) the effect of limitations that
the merger agreement places on Panbela’s ability to operate its
business or engage in other transactions during the pendency of the
transaction; (vii) the nature, cost and outcome of future
litigation and other legal proceedings, including any such
proceedings relating to the transactions and instituted
against Panbela and others; (viii) the risk that the transaction
may involve unexpected costs, liabilities or delays; (ix)
other economic, business, competitive, legal, regulatory, and/or
tax factors; ( x ) our ability and the combined
company’s ability to obtain additional funding to complete
clinical trials; (ii) progress and success of our Phase 1 clinical
trial; (iii) the impact of the current COVID-19 pandemic on our
ability to complete monitoring and reporting in our current
clinical trial and procure the active ingredient; (iv) our ability
to demonstrate the safety and effectiveness of our SBP-101 product
candidate (v) our ability to obtain regulatory approvals for our
SBP-101 product candidate in the United States, the European
Union or other international markets; (vi) the market acceptance
and level of future sales of our SBP-101 product candidate; (vii)
the cost and delays in product development that may result from
changes in regulatory oversight applicable to our SBP-101
product candidate; (viii) the rate of progress in establishing
reimbursement arrangements with third-party payors; (ix) the effect
of competing technological and market developments; (x) the costs
involved in filing and prosecuting patent applications and
enforcing or defending patent claims; and (xi) such other factors
as discussed in Part I, Item 1A under the caption “Risk Factors” in
our most recent Annual Report on Form 10-K, any additional risks
presented in our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K. Any forward-looking statement made by us in
this press release is based on information currently available to
us and speaks only as of the date on which it is made. We
undertake no obligation to publicly update any forward-looking
statement or reasons why actual results would differ from those
anticipated in any such forward-looking statement, whether
written or oral, whether as a result of new
information, future developments or otherwise.
Contact Information:
Investors:James CarbonaraHayden IR(646)
755-7412james@haydenir.com
Media:Tammy GroenePanbela Therapeutics, Inc.(952) 479-1196 ext.
170IR@panbela.com
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Panbela Therapeutics (NASDAQ:PBLA)
Historical Stock Chart
From Sep 2023 to Sep 2024